As the Focus on Psychedelic Stocks Increases, So Do the Valuations
As the Focus on Psychedelic Stocks Increases, So Do the Valuations The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations. With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate the major factors of success or failure in the industry. There are various steps that companies take to have a drug approved and to successfully complete them it takes years and tens of millions of dollars. The further ahead a company moves in the approval process, the more valuable the co...